# Study Evaluating Sirolimus in the Treatment of Kidney Transplant

> **NCT00282217** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 100 (—)

## Conditions studied

- Kidney Failure
- Kidney Diseases

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00282217
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (—)
- **Last updated:** 2007-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282217, "Study Evaluating Sirolimus in the Treatment of Kidney Transplant". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00282217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*